Recent reports from in-Pharma Technologist.com illustrate that production within the life science industry is off to an impressive start in this new year.
For example, the Web site reports that Cel-Sci has validated production equipment at its Baltimore, MD, GMP facility for aseptic filling and is ready to commence manufacture of its cancer drug Multikine. Once Cel-Sci has produced enough material for a Phase III trial of the drug, it says it will offer contract manufacturing services from the facility.
